Valley National Advisers Inc. Decreases Stock Holdings in Cencora, Inc. $COR

Valley National Advisers Inc. lessened its holdings in Cencora, Inc. (NYSE:COR) by 97.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 227 shares of the company’s stock after selling 7,557 shares during the period. Valley National Advisers Inc.’s holdings in Cencora were worth $71,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in COR. Norges Bank purchased a new position in Cencora in the second quarter valued at about $695,215,000. Artisan Partners Limited Partnership purchased a new stake in shares of Cencora in the second quarter worth about $411,888,000. Vanguard Group Inc. grew its stake in shares of Cencora by 5.3% in the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after buying an additional 1,125,661 shares in the last quarter. Viking Global Investors LP raised its holdings in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after buying an additional 1,013,913 shares during the period. Finally, Ameriprise Financial Inc. raised its holdings in shares of Cencora by 228.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 974,505 shares of the company’s stock valued at $292,207,000 after buying an additional 677,952 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 20,317 shares of company stock worth $7,009,260 over the last quarter. 10.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on COR. Wells Fargo & Company increased their price objective on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Weiss Ratings restated a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 22nd. Evercore ISI set a $400.00 price target on shares of Cencora and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Barclays started coverage on shares of Cencora in a report on Monday, December 8th. They issued an “overweight” rating and a $400.00 price objective on the stock. Finally, UBS Group raised their target price on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $373.25.

Cencora Stock Performance

Shares of Cencora stock opened at $341.12 on Monday. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $377.54. The firm’s 50-day simple moving average is $348.66 and its 200-day simple moving average is $315.28. The firm has a market cap of $66.17 billion, a PE ratio of 42.91, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the business earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. Cencora’s payout ratio is 30.19%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.